Meaning and Methodology of Fundamental Analysis (2025)

Dividend-paying stocks: return, risk, strategy

Balance sheet and income statement made clear 2025

What is a stock exchange? Operation, actors, examples

Stock Valuation 2025: A Beginner's Guide

Objective Corporation (ASX:OCL) share fundamentals, overview



Objective Corporation is an Australian software company founded in 1987, specializing in content and records management and regulatory workflow software for government and regulated industry sectors (e.g. defense institutions, military, etc.). The company is still led by founder Tony Walls today, who owns approximately 64.81% of the shares through the TBW Group holding company, one of the highest founder ownership ratios on the Aust

Objective Corporation (ASX:OCL) share fundamentals, overview



Objective Corporation is an Australian software company founded in 1987, specializing in content and records management and regulatory workflow software for government and regulated industry sectors (e.g. defense institutions, military,

Objective Corporation Stock Analysis – State Within State

What does the stock market report section contain?



The stock price has been in a steady decline ahead of the Computer Modelling Group's 2027 Q1 report, as the transformation of the mature oil company into a serial acquisition company is taking longer than expected. That's why it deserves a place in the "Reporting from the Stock Exchange" section, which is always an update on fundamental analysis. But what is it all about?



The column is a kind of compass for investors, helping them navigate

What does the stock market report section contain?



The stock price has been in a steady decline ahead of the Computer Modelling Group's 2027 Q1 report, as the transformation of the mature oil company into a serial acquisition company is taking longer than expected. That's why it deserves a place 

Computer Modeling Group 2027 Q1 - Turnarounds seldom turn?

Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.

The trust seeks to achieve its investment objective by holding a portfolio of the common stocks that are included in the index (the "Portfolio"), with the weight of each stock in the Portfolio substantially corresponding to the weight of such stock in the index.

Liminatus Pharma secures $1.9M cash via warrant exercises

Liminatus Pharma notifies Nasdaq of impending delisting; plans to appeal

Accounts payable

Total current assets

Cash

Short/Current long term debt

Goodwill

Intangible assets

Net tangible assets

Property, plant and equipment

Net receivables

Shareholder's equity

Total assets

Total current liabilities

Total liabilities

Balance Sheet

Capital expenditures (TTM)

Operating cash flow (TTM)

Dividends paid (TTM)

Free cash flow (TTM)

Cash flow

DGR 10 years

DGR 15 years

DGR 3 years

DGR 5 years

DGR MR

DGR TTM

EPS growth (5y forward)

EPS growth (5y)

Time since last change announced

Dividend growth

Average yield

Yield as % of max yield

Discount to avg yield

Dividend per share

Dividend yield

Payout frequency

Maximum yield

Minimum yield

Upside potential

Dividend yield - 5y

Avg time to new high

Avg drop from high

Max time to new high

Highest price drop

Date of highest drop

Current price drop from All-time high

Downside potential

CCC status

Years of growth

EPS (1y forward)

EPS (TTM)

Ex-div date

Cash Return on Invested Capital

Return on Assets

Return on Equity

Return on Invested Capital

Financial returns

Gross profit (TTM)

Net income (TTM)

Operating income (TTM)

Revenue (TTM)

Income statement

Gross margin (TTM)

Operating margin (TTM)

Profit margin (TTM)

Margins

Average

Forward

Payout ratio

FCF per share (TTM)

Current share count

Per share

Current yield distribution

Yield at 0% (Max)

Yield at 10%

Yield at 100% (Min)

Yield at 20%

Yield at 50% (Median)

Yield at 80%

Yield at 90%

Yield distribution (inverse percentile) - 5y

All-time high

1y analyst estimate

Beta

Price at close

Daily high

Daily low

Open

Daily Volume

Next earnings date

Stock chart

EV to Sales

Price to Book

Price to Sales

Valuation (Sales/Book Value)

EV to EBITDA

Trailing P/E

Price to EBITDA

Price to FCF

Price to OCF

Valuation Ratios

	LIMNW	S&P500
Current price drop from All-time high	-76.27%	-2.53%
Highest price drop	-78.03%	-56.47%
Date of highest drop	13 Jan 2026	9 Mar 2009
Avg drop from high	-38.11%	-10.68%
Avg time to new high	12 days	12 days
Max time to new high	46 days	1805 days

EPS (TTM)	-0.12
Dividend per share	0.00
Ex-div date	-
Next earnings date	-

LIMNW

Objective Corporation Stock Analysis – State Within State

Stock information

What is a stock exchange? Operation, actors, examples

Stock chart

Downside potential